Chromosomal Disorders is an indication for drug development with over 360 pipeline drugs currently active. According to GlobalData, preregistered drugs for Chromosomal Disorders have a 75% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Chromosomal Disorders compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Chromosomal Disorders overview
Chromosomal disorders arise from irregularities in chromosome structure or number, encompassing two main categories: numerical abnormalities and structural abnormalities. Numerical irregularities involve deviations from the standard chromosome count, as seen in conditions like Down syndrome (with an extra chromosome 21) or Turner syndrome (with only one X chromosome in females). In contrast, structural abnormalities result from changes in individual chromosome structures, such as deletions, duplications, translocations, inversions, and rings. These disorders can profoundly impact an individual’s development, causing both physical and intellectual challenges. Some are inherited, while others occur spontaneously during cell division, emphasizing the need for comprehensive genetic studies, often including parental chromosome analysis, to comprehend and address chromosomal disorders
For a complete picture of PTSR and LoA scores for drugs in Chromosomal Disorders, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
